A pharmacy sale listing is a marketing document, not a financial disclosure. It's written to get enquiries, not to tell you the risks. Knowing what each field really represents, and what the listing leaves out, is the first practical skill you need as a buyer.
Take a typical listing field by field and you'll find each number raises a question rather than answering one, and you'll need to verify it before an offer makes sense. For the verification process itself, see the financial due diligence guide. For the full buying sequence from first contact to completion, see the complete buyer checklist.
What a pharmacy sale listing is really telling you
The headline asking price and turnover figure are the least useful numbers in a pharmacy listing. What matters is the NHS items dispensed per month, the income mix between NHS and non-NHS sources, and how the asking price relates to adjusted EBITDA and goodwill. None of those relationships can be verified from the listing. A listing that looks compelling on turnover may tell a very different story once the income split, the adjusted EBITDA workings, and the contract position are examined.
The anatomy of a listing, field by field
Take the fields one at a time. Each one conceals more than it reveals.
| Listing field | What it means | What it does not tell you | Verification step |
|---|---|---|---|
| NHS turnover | Reimbursement (Drug Tariff prices) and remuneration (fees and service payments) received from the NHSBSA under the Community Pharmacy Contractual Framework. Income is contract-driven and reimbursement-based, not shop takings. | The margin on that turnover; how Category M prices moved over the period (DHSC resets them each quarter); and whether the figure is the payments received or includes an advance still to be reconciled. | Ask the seller for 24 months of NHSBSA's FP34 Schedules of Payment and reconcile them to the accounts. |
| Total turnover | NHS turnover plus OTC retail sales, private services, and any other income lines including Pharmacy First and enhanced service payments. | The margin profile of each income line. OTC retail and private services carry a very different VAT treatment and margin from NHS dispensing. See how pharmacy VAT works. | Ask for an income split showing NHS, OTC retail and private income separately, and map the VAT treatment of each. |
| Items per month | The number of prescription items dispensed monthly under the NHS contract. This is the primary volume driver of NHS income and of goodwill value. | Whether the volume is stable, growing or declining; how concentrated it is on one or two prescribing GP surgeries; and whether it is comparable with neighbouring pharmacies or an outlier. | Request the NHSBSA dispensing data for at least 24 months. Check for trend and prescriber concentration. |
| Asking price | The seller's stated price, built from a multiple of adjusted EBITDA or a pence-per-item benchmark and an assessment of goodwill. Goodwill dominates pharmacy pricing because it is driven by the NHS contract and item volume. | The multiple used, the EBITDA figure it is applied to, or the adjustments made to arrive at that EBITDA. None of this is disclosed in the listing. | Request the seller's valuation workings. Use the purchase affordability calculator to see whether your own, cautious profit figure covers the repayments on that price. |
| Adjusted EBITDA | Earnings before interest, tax, depreciation and amortisation, with one-off or non-recurring items removed. The seller prepares this figure. | What has been adjusted out and why. Adjustments can include owner remuneration set below market rate, non-recurring costs removed, and property charges treated inconsistently. | Request the full EBITDA bridge showing every adjustment. Rebuild the EBITDA on normalised assumptions. |
| Freehold / leasehold | Whether the property interest comes with the business. A freehold purchase includes the property asset; a leasehold purchase transfers the lease. | The lease term remaining, the rent level relative to market, the rent review mechanism, whether there are break clauses, and whether landlord consent is required for assignment. | Obtain a copy of the lease. Check unexpired term, rent review dates and any landlord alienation restrictions. |
| Staff / TUPE | An indication of the workforce. TUPE (Transfer of Undertakings, Protection of Employment) applies on a business transfer, preserving existing employees' terms and conditions. | Individual employment terms, any ongoing HR disputes, whether staff costs have been normalised in the EBITDA, or the employer NIC obligation on the inherited payroll (employer NIC is 15% above the £5,000 secondary threshold from April 2025). | Request a staff schedule with roles, hours, pay rates and length of service. Check for any settlement agreements or ongoing disputes. |
Why items per month is the number that matters most
Pharmacy income is contract-driven, not till-driven. The NHS reimburses the pharmacy for each prescription item dispensed at Drug Tariff prices and pays remuneration fees on top. Items per month is therefore the volume measure that underpins NHS dispensing income directly.
It also drives goodwill. Goodwill dominates pharmacy pricing because it is tied to the NHS contract and the dispensing volume that contract sustains. A pharmacy with a stable, high-volume NHS contract commands a different goodwill premium from one with a declining or geographically vulnerable volume, regardless of what the headline turnover says.
The items per month figure in a listing is a snapshot. Trend matters more than the single number. A pharmacy that has dispensed a consistent volume over 24 months against a spread of prescribers is a fundamentally different proposition from one whose volume is concentrated on a single GP surgery or has been declining for 18 months. The listing will not tell you which type you are looking at.
More items also means a bigger cash gap when you take over, because of the FP34 payment cycle (see the working-capital point below).
Adjusted EBITDA and asking price: what the listing implies and why you cannot verify it
Pharmacies are priced on a multiple of adjusted EBITDA and on pence-per-item benchmarks, with goodwill treated as a separate component reflecting the NHS contract's value. We treat valuation as method-level only: the multiple used in any given deal is market-specific and cannot be reliably stated as a benchmark.
What a buyer needs to understand is the chain of decisions behind a listing's asking price:
- Reported EBITDA comes from the accounts. It reflects actual performance, including any owner-specific costs or choices about remuneration and property.
- Adjustments are made by the seller to normalise the figure: removing a below-market owner salary, adding back a one-off cost, or stripping out an above-market rent paid to a connected party. Each adjustment is a judgement call. The listing discloses none of them.
- Adjusted EBITDA is the result after those adjustments. It is the figure a multiple will be applied to. If the adjustments are aggressive, the adjusted EBITDA is higher than underlying performance warrants.
- Goodwill is added or the multiple implicitly captures it. The asking price is the result.
A buyer who accepts the adjusted EBITDA without rebuilding it from the accounts is accepting the seller's characterisation of what the business earns. Rebuilding it on normalised assumptions is one of the first tasks in financial due diligence. See the due diligence guide for the full workstream.
There's a corporation tax dimension too. If your company buys the business, relief on goodwill is restricted for a company buyer: it's a fixed 6.5% a year, and only if the business comes with qualifying IP assets. So the structure affects the real cost of the goodwill element of the price. See share vs asset purchase for the structuring implications.
Add the purchase price, deposit, loan terms and projected profit to see the monthly repayment, the post-tax cash cover and the stamp duty or SDLT on a share deal against an asset deal.
Pharmacy Purchase Affordability Calculator
Enter the purchase price, deposit, loan terms and projected pharmacy profit to see your estimated loan repayments, how well trading cash flow covers the debt, and the acquisition tax cost for a share deal versus an asset deal. Every figure already in the boxes is an example, so replace it with your own; the result on your deal depends on how it's structured.
The agreed headline price for the pharmacy. Enter the actual figure from your heads of terms.
The amount you are putting in from your own funds. The rest is assumed to be financed by a commercial loan.
The term your lender offers. Shorter terms mean higher repayments but less total interest.
The rate quoted by the lender. The rate you are offered depends on lender, term and loan-to-value.
The part of the price that buys land or buildings: a freehold, or what you pay for a lease. Leave at 0 if no property is being bought. SDLT is charged on this figure only, never on goodwill or the NHS contract.
Only if you're taking a new lease of the premises. SDLT is due on the rent's net present value at 1% from £150,001 to £5 million and 2% above. HMRC's SDLT calculator works the figure out from the rent and the term.
The adjusted EBITDA or trading profit you expect after your salary, before loan interest and tax. The tool takes the first year's interest off before working out corporation tax.
Your result
Your answer's ready. Press below to see it.
What the listing does not tell you
These facts carry the risk and the economics of a pharmacy purchase, and you won't find any of them in a listing.
Working-capital requirement from day one
Under the FP34 submission cycle you declare a month's prescriptions by the 5th of the next, NHSBSA pays a 100% estimated advance around the 10th, and the reconciliation follows two months after you submit. So your first month's stock and wages go out before any NHS money comes in, while payments for the seller's dispensing are still landing after completion. The more items a month, the bigger the gap, and the listing says nothing about which NHSBSA payments are still to come or who keeps them.
Category M margin trend
Drug Tariff prices are set centrally, and DHSC resets Category M prices each quarter, so a listed gross margin is a snapshot. Whether it's been shrinking over the past 24 months shows up only when you reconcile the FP34 remittances to the accounts month by month. Category M clawbacks explained covers the mechanism.
The VAT mix
NHS dispensing is zero-rated for VAT and over-the-counter medicines are standard-rated, and zero-rated dispensing still counts towards the £90,000 registration threshold. A listing's turnover lumps both together, so the retail scheme in use, whether it makes the Retail Chemist Adjustment and how much VAT comes back are all invisible. That matters for day-one cash and for checking the current owner has got VAT right.
Contract-transfer risk
The NHS pharmaceutical contract doesn't transfer automatically on a change of ownership (NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013). Buy the assets and you need NHS England's approval to take the seller's place on the pharmaceutical list; buy the company and it has to tell NHS England of new directors or a new superintendent. The premises entry in the GPhC register also turns on who is lawfully running the pharmacy business there (Medicines Act 1968 s74B). The buying checklist sets out the notification and approval sequence.
Enhanced service and Pharmacy First agreements
Pharmacy First and other advanced and enhanced service agreements are income lines in their own right: each Pharmacy First clinical pathway consultation earns £17 in 2026/27. Whether they transfer to a new owner or require re-application is not disclosed in a listing. A pharmacy with a high Pharmacy First income is a different profile from one whose total turnover is mostly dispensing volume.
Want this checked against your specific situation?
Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.
The sanity-check questions to ask before you enquire
Before making a formal enquiry, a prospective buyer should be able to answer these questions, or establish why they cannot yet do so:
- What is the items-per-month figure and is it consistent over the last two years? Has the listing disclosed a trend or a snapshot?
- What proportion of NHS income comes from the top one or two prescribing GP surgeries? Ask, because it's the concentration risk behind the volume.
- Is the EBITDA figure in the listing reported or adjusted? If adjusted, what is the adjustment narrative?
- What is the lease term remaining and what are the rent review conditions? Is landlord consent needed for assignment?
- Would a cautious profit figure cover the repayments on the asking price? Put the price, your deposit and that profit into the purchase affordability calculator to see the monthly repayment and the post-tax cash cover before committing time to the deal.
- Is the listing for a share sale or an asset sale? The answer determines stamp duty, SDLT, TUPE mechanics, and whether you need NHS England's approval to take over the pharmaceutical listing.
- Are there any advanced or enhanced service agreements (Pharmacy First, smoking cessation, blood pressure checks) in the income, and if so are they transferable?
If a broker or seller can't answer these at the information memorandum stage, that tells you something about how the rest of the process will go.
From listing to offer: what happens next
A listing starts a process; it isn't the basis for a decision. After the first enquiry come the information memorandum, management meetings, heads of terms, and then financial and legal due diligence before any offer is final. The stages are in the complete buyer checklist, testing the listing's figures is in the financial due diligence guide, and the full cost once a price is agreed is in the cost of buying a pharmacy. The buying a pharmacy hub brings the guides, calculators and services together.